Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–188 of 188 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ctDNA Clear all
Recruiting No phase listed Observational

CtDNA Based MRD Testing for NAC Monitoring in TNBC

NCT06230185
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Interventions
Not listed
Lead sponsor
Personalis Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
14
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions
Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer

NCT06445114
View directory record Official record
Conditions
Oropharyngeal Cancer, Carcinoma
Interventions
Cisplatin
Drug
Lead sponsor
Zachary Zumsteg
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Beverly Hills, California • Los Angeles, California • Tarzana, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934
View directory record Official record
Conditions
ER-Positive HER2-Negative Breast Cancer
Interventions
AZD9833, AZD9833 Placebo, Anastrozole, Anastrozole placebo, Letrozole, Letrozole placebo, Palbociclib, Abemaciclib, Luteinizing hormone-releasing hormone (LHRH) agonist, Ribociclib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
64
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

NCT06333678
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Sotorasib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Miami, Florida • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Completed No phase listed Observational

Circulating Tumor DNA As Liquid Biopsy in Patients with Stage IV Solid Tumors, a Feasibility Study At MUSC HCC

NCT03302325
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
research blood draws
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 28, 2026, 5:38 AM EDT
Withdrawn No phase listed Observational

Response Assessment by Circulating Tumor DNA in Patients With Locally Advanced Rectal Cancer

NCT04670588
View directory record Official record
Conditions
Rectal Cancer
Interventions
Circulating tumor DNA(ctDNA) level measurement
Diagnostic Test
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting No phase listed Observational

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178
View directory record Official record
Conditions
Breast Cancer, TNBC - Triple-Negative Breast Cancer, HR Positive/HER-2 Negative Breast Cancer, HER2 + Breast Cancer, Early Stage Breast Cancer
Interventions
There are no interventions in this observational study.
Other
Lead sponsor
Tempus AI
Industry
Eligibility
18 Years to 99 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Whittier, California • Weston, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Phase 2 Interventional

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

NCT06617858
View directory record Official record
Conditions
Colorectal Cancer
Interventions
AMB-05X
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Suspended Phase 2 Interventional Accepts healthy volunteers

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage I, Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III
Interventions
AVENIO ctDNA Surveillance Kit, Durvalumab, Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
Device · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Datopotamab Deruxtecan, Rilvegostomig, Carboplatin, Cisplatin, Etoposide, Pemetrexed, Vinorelbine, UFT
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
37
States / cities
Tucson, Arizona • Duarte, California • Glendale, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Phase 1 Interventional

Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas

NCT04920032
View directory record Official record
Conditions
Colon Adenocarcinoma, Colorectal Cancer
Interventions
TAS-102, Irinotecan, Standard Treatment, Signatera MRD ctDNA Assay
Drug · Combination Product · Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting No phase listed Observational

Circulating Tumor DNA in High Risk Localized Prostate Cancer

NCT07222436
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 28, 2026, 5:38 AM EDT
Recruiting Not applicable Interventional

A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.

NCT07830225
View directory record Official record
Conditions
Melanoma (Skin Cancer)
Interventions
A Pilot Study of ctDNA-guided immune checkpoint inhibitor duration in patients with advanced melanoma
Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Not listed No phase listed Observational

Recurrence Monitoring in NSCLC Using Circulating Tumor DNA

NCT03878537
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Oct 28, 2026, 5:38 AM EDT
Terminated Phase 2 Interventional Results available

Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

NCT04849364
View directory record Official record
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Capecitabine, Talazoparib, Pembrolizumab, Inavolisib
Drug
Lead sponsor
Bryan Schneider, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Hollywood, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 28, 2026, 5:38 AM EDT
Active, not recruiting No phase listed Observational

Early Treatment ctDNA Dynamics to Predict Response to Chemotherapy

NCT07122466
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
Tumor DNA circulating in the bloodstream (circulating tumor DNA; ctDNA)
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 28, 2026, 5:38 AM EDT
Not yet recruiting Early Phase 1 Interventional

Trial of ctDNA of Guidance to Determine PostOperative Radiation Therapy

NCT06979661
View directory record Official record
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Lung Cancer Recurrent
Interventions
Haystack™ ctDNA Assay
Diagnostic Test
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 28, 2026, 5:38 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PATHFINDER 2: A Multi-Cancer Early Detection Study

NCT05155605
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
35,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
55
States / cities
Auburn, California • Davis, California • Elk Grove, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 28, 2026, 5:38 AM EDT